HBeAg 阴性/抗 HBe 阳性慢性乙型肝炎：40 年历史

StephenW

HBeAg 阴性/抗 HBe 阳性慢性乙型肝炎：40 年历史
费鲁乔博尼诺 1 , 皮耶罗 Colombatto 2 , 毛里齐亚 R 布鲁内托 1 2
隶属关系
隶属关系

    1
    国家研究委员会生物结构和生物成像研究所，Via De Amicis 95, 80145 Naples, Italy。
    2
    比萨大学医院托斯卡纳地区慢性肝病和癌症参考中心肝炎病毒分子遗传学和病理学实验室，肝病学部门和实验室，Via Paradisa 2, 56124 Pisa, Italy。

    PMID：36016312 PMCID：PMC9416321 DOI：10.3390/v14081691

免费 PMC 文章
抽象的

乙型肝炎“e”抗原 (HBeAg) 阴性慢性乙型肝炎 (CHB) 自在地中海地区发现 40 年以来，已成为全球最普遍的 HBV 诱发的肝病形式，也是由 HBV 感染引起的主要医疗保健负担。过去几十年积累的大量知识为病毒核心蛋白的结构和非结构形式表达的双峰动态提供了一致的证据，这与 HBV 感染的不同病毒学和临床病理学结果相关。在没有血清 HBeAg 的情况下，HBV 复制的存在和持续会导致并维持病毒相关的肝损伤。因此，在临床实践中，必须筛查 HBeAg 阴性感染的 HBV 携带者，以便早期诊断 HBeAg 阴性 CHB，因为早期开始抗病毒治疗可以治愈 HBV 引起的肝病。

关键词：乙肝；乙肝病毒DNA； HBeAg; HBeAg 缺陷型 HBV 突变体；抗HBe；慢性乙型肝炎。
利益冲突声明

F.B.：雅培、DiaPro、DiaSorin、Echosens、Fujirebio 和罗氏的顾问委员会和发言人局。 M.R.B.：咨询委员会和发言人局 AbbVie、Gilead、Janssen、EISAI-MSD、Roche。

StephenW

HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History
Ferruccio Bonino  1 , Piero Colombatto  2 , Maurizia R Brunetto  1   2
Affiliations
Affiliations

    1
    Institute of Biostructure and Bioimaging, National Research Council, Via De Amicis 95, 80145 Naples, Italy.
    2
    Hepatology Unit and Laboratory of Molecular Genetics and Pathology of Hepatitis Viruses, Reference Center of the Tuscany Region for Chronic Liver Disease and Cancer, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy.

    PMID: 36016312 PMCID: PMC9416321 DOI: 10.3390/v14081691

Free PMC article
Abstract

Hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B (CHB), 40 years since discovery in the Mediterranean area, has become the most prevalent form of HBV-induced liver disease worldwide and a major health care burden caused by HBV infection. A great deal of knowledge accumulated over the last decades provides consistent evidence on the bimodal dynamics of the expression of structural and non-structural forms of the viral core proteins which associate with different virologic and clinic-pathologic outcomes of HBV infection. In absence of serum HBeAg, the presence and persistence of HBV replication causes and maintains virus-related liver injury. Thus, in clinical practice it is mandatory to screen HBV carriers with HBeAg-negative infection for the early diagnosis of HBeAg-negative CHB since antiviral therapy can cure HBV-induced liver disease when started at early stages.

Keywords: HBV; HBV-DNA; HBeAg; HBeAg defective HBV mutants; anti-HBe; chronic hepatitis B.
Conflict of interest statement

F.B.: Advisory Board and Speakers Bureau for Abbott, DiaPro, DiaSorin, Echosens, Fujirebio, and Roche. M.R.B.: Advisory Board and Speakers’ Bureau AbbVie, Gilead, Janssen, EISAI-MSD, Roche.

StephenW

https://www.mdpi.com/1999-4915/14/8/1691/pdf?version=1660113771